SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGraft Polymer PLC Regulatory News (GPL)

  • There is currently no data for GPL

Director Share Purchase

16 May 2023 14:08

RNS Number : 6117Z
Graft Polymer (UK) PLC
16 May 2023
Β 

Β 

16 May 2023

Β 

Graft Polymer (UK) Plc

("Graft Polymer", the "Company", and together with its subsidiaries, the "Group")

Β 

Director Share Purchase

Β 

Β 

Graft Polymer (UK) Plc, a business focused on the development and commercial production of modified polymer solutions including additives, alloys, synthesis, and drug delivery systems, announces that on 15 May 2023, Alex Brooks, Non-Executive Director of Graft Polymer, acquired 56,399 Ordinary Shares at an average price of 4.6 pence per Ordinary Share. Following this acquisition of shares, Alex Brooks has a total beneficial interest in 475,004 Ordinary Shares, representing approximately 0.46% of the total issued share capital of the Company.

Β 

Β 

Β 

Β -Ends-

Β 

Authorised for release by the board of directors, for further information please contact:

Β 

Graft Polymer (UK) Plc (via St Brides Partners)

St Brides Partners (Public Relations)

Roby Zomer, Non Executive Chairman

Yifat Steuer, CFO and Executive Director

https://www.graftpolymer.com

Catherine Leftley

Ana Ribeiro

Max Bennett

graftpolymer@stbridespartners.co.uk

Turner Pope Investments (Broker)

Β 

James Pope

Andy Thacker

+44 20 3657 0050

Β 

Β 

About Graft Polymer

Β 

Graft Polymer is a London Stock Exchange listed company (GPL.L) with a cutting-edge, cash-flow positive, research and development (R&D) and manufacturing facility based in Slovenia which has already introduced more than 50 products to the market. The core business of the Group comprises polymer modification and drug delivery system developments. The Group has developed a proprietary set of polymer modification technologies which uses recycled raw materials and a closed loop system to reduce waste. Graft Polymer's technology can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing, reducing material consumption, widening the choice of feedstocks, and reducing costs.

Graft Polymer has two divisions: the first division focusses on polymer modification; the second is GraftBio which develops IP for Bio/Pharma applications (including a drug delivery system to support and provide solutions to the market, which had been heavily impacted by the COVID-19 pandemic). A significant milestone was reached in May 2022 when the Slovenian manufacturing facility was granted a Hazard Analysis and Critical Control Point (HACCP) Certificate.

Environment, Social and Governance is at the forefront of the Group's strategy and the facility in Slovenia has been granted ISO 14001 accreditation in recognition of the environmental management systems in place to reduce waste. Graft Polymer only uses REACH and ROHS certificated raw materials instead of toxic raw materials, and its extensive R&D programme has also developed specialised recycling polymer additives which increases the strength of recycled blends and plastic products whilst also reducing plastic waste by between 40 and 50 per cent.

Β 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Β 

Details of the person discharging managerial responsibilities / person closely associated

Β 

a)

Β 

Name

Β 

Β 

Alex Brooks

Β 

2

Β 

Reason for the notification

Β 

a)

Β 

Position/status

Β 

Β 

Non-Executive Director of Graft Polymer (UK) Plc

b)

Β 

Initial notification /Amendment

Β 

Β 

Initial notification

3

Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Β 

a)

Β 

Name

Β 

Β 

Graft Polymer (UK) Plc

b)

Β 

LEI

Β 

Β 

2138005PH7OJRCRPUD88

4

Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β 

Β 

a)

Β 

Description of the financial instrument, type of instrument

Ordinary Shares

Identification code

GB00BMD1Z199

Β 

b)

Β 

Nature of the transaction

Β 

Β 

On market purchase of shares

c)

Β 

Price(s) and volume(s)

Price(s)

Volume(s)

4.6p

56,399

d)

Β 

Aggregated information

N/A Single Transaction

- Aggregated volume

- Price

e)

Β 

Date of the transaction

Β 

Β 

15 May 2023

f)

Β 

Place of the transaction

Β 

Β 

London Stock Exchange

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHSFFFDMEDSESI
12
Date   Source Headline
14th Jan 20257:00 amRNSChange of Name to Solvonis Therapeutics plc
6th Jan 20252:27 pmRNSResult of General Meeting and change of name
16th Dec 20247:00 amRNSProposed acquisition of Awakn Life Sciences Corp
11th Dec 20247:00 amRNSInitial Results University of Nottingham
3rd Dec 20249:44 amRNSNotice of GM and proposed name change
15th Oct 20247:00 amRNSResearch Agreement
4th Oct 20247:00 amRNSResearch and development update
26th Sep 20247:00 amRNSDirectorate Change and grant of options
13th Sep 20247:00 amRNSHalf-year Report
28th Aug 20247:00 amRNSCommercial Collaboration Progress Update
13th Aug 20247:00 amRNSHolding(s) in Company
12th Aug 202410:21 amRNSDirectorate Change
8th Aug 202410:08 amRNSHolding(s) in Company
1st Aug 20247:00 amRNSDirectorate Change
31st Jul 20245:00 pmRNSTotal Voting Rights
23rd Jul 20241:59 pmRNSHolding(s) in Company
23rd Jul 20247:00 amRNSCommercial Collaboration
18th Jul 20247:00 amRNSCommercial Collaboration
17th Jul 20249:28 amRNSHolding(s) in Company
15th Jul 20247:00 amRNSDirectorate Change
12th Jul 20247:00 amRNSHolding(s) in Company
12th Jul 20247:00 amRNSHolding(s) in Company
11th Jul 20249:36 amRNSHolding(s) in Company
11th Jul 20249:27 amRNSHolding(s) in Company
11th Jul 20249:26 amRNSHolding(s) in Company
11th Jul 20249:20 amRNSHolding(s) in Company
11th Jul 20249:20 amRNSHolding(s) in Company
11th Jul 20247:00 amRNSPatent Filings
10th Jul 20244:24 pmRNSHolding(s) in Company
10th Jul 20248:10 amRNSAdmission & Director/PDMR Shareholding
3rd Jul 20242:29 pmRNSPublication of a Prospectus
28th Jun 202412:58 pmRNSResult of AGM
7th Jun 20247:00 amRNSBusiness Update
4th Jun 20244:26 pmRNSNotice of AGM
31st May 20247:00 amRNSPatent Application
28th May 20247:00 amRNSRegulatory Application
9th May 20247:00 amRNSUpdate on recent developments
7th May 20247:00 amRNSGrant of Haemostatic Hydrogel Patent
3rd May 20247:00 amRNSDivestment of Graft Polymer d.o.o – Slo facility
2nd May 20247:00 amRNSReplacement of Chief Executive Officer
30th Apr 20245:05 pmRNSAnnual Financial Report
23rd Apr 20244:17 pmRNSLoan facility update
15th Mar 20247:00 amRNSChairman & Directorate Change & Financial Update
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSGM Statement
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSDirector/PDMR Shareholding
8th Jan 20245:00 pmRNSHolding(s) in Company
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.